PHIO is trading at $1 with early-stage Phase 1 cancer immunotherapy showing complete tumor responses, positioned as a potential acquisition target following Moderna's Phase 3 success and massive valuation spike. Key risks include typical biotech hazards: Phase 1 data rarely translates to later stages, tiny sample sizes, high failure probability, and extreme speculative nature of pre-Phase 2 plays.